Mersana Therapeutics Overview
- Founded
-
2001

- Status
-
Public
- Employees
-
169

- Stock Symbol
-
MRSN

- Share Price
-
$7.45
- (As of Thursday Closing)
Mersana Therapeutics General Information
Description
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. The Company's early stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
Contact Information
- 840 Memorial Drive
- Cambridge, MA 02139
- United States
Mersana Therapeutics Timeline
Mersana Therapeutics Stock Performance
(As of Thursday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$7.45 | $7.82 | $2.68 - $14.80 | $760M | 97.2M | 1.53M | -$2.44 |
Mersana Therapeutics Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
---|---|---|---|---|
EV | 255,716 | 274,803 | 1,568,610 | 155,855 |
Revenue | 6,342 | 43 | 828 | 42,123 |
EBITDA | (190,866) | (168,003) | (87,100) | (28,955) |
Net Income | (193,931) | (170,060) | (88,045) | (28,208) |
Total Assets | 252,351 | 206,111 | 273,399 | 107,541 |
Total Debt | 37,427 | 38,176 | 16,572 | 7,764 |
Mersana Therapeutics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Mersana Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
Mersana Therapeutics Comparisons
Industry
Mersana Therapeutics Competitors (62)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Mabworks Biotech | Private Equity-Backed | Beijing, China | 000 | 00000 | 0000000 0000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Boston, MA | 0 | 00000 | 000000000 | 00000 |
00000000 | Private Equity-Backed | San Carlos, CA | 00 | 00000 | 000000000 | 00000 |
000000000 | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
Mersana Therapeutics Patents
Mersana Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20210220477-A1 | Site specific antibody-drug conjugates with peptide-containing linkers | Pending | 09-Jan-2020 | 000000000 | |
US-11155567-B2 | Sting agonist compounds and methods of use | Active | 02-Aug-2019 | 0000000000 | 00 |
US-20210032269-A1 | Sting agonist compounds and methods of use | Granted | 02-Aug-2019 | 0000000000 | |
EP-3717021-A1 | Pyrrolobenzodiazepine antibody conjugates | Pending | 27-Nov-2017 | 00000000000 | |
JP-2020525441-A | Drug-bearing polymer scaffolds and methods of making protein-polymer-drug conjugates | Pending | 22-Jun-2017 | A61K38/08 |
Mersana Therapeutics Executive Team (23)
Mersana Therapeutics Board Members (20)
Name | Representing | Role | Since |
---|---|---|---|
Allene Diaz | Mersana Therapeutics | Board Member | 000 0000 |
Andrew Hack Ph.D | Self | Board Member | 000 0000 |
Anna Protopapas | Mersana Therapeutics | Chief Executive Officer, President & Board Member | 000 0000 |
David Mott | Self | Chairman | 000 0000 |
Kristen Hege MD | Self | Board Member | 000 0000 |
Mersana Therapeutics Signals
Mersana Therapeutics Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|